World Asset Management Inc acquired a new stake in shares of Insulet Co. (NASDAQ:PODD) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 1,136 shares of the medical instruments supplier’s stock, valued at approximately $221,000.

Other institutional investors have also recently modified their holdings of the company. Guggenheim Capital LLC grew its position in Insulet by 19.4% in the fourth quarter. Guggenheim Capital LLC now owns 2,251 shares of the medical instruments supplier’s stock worth $385,000 after acquiring an additional 366 shares in the last quarter. AQR Capital Management LLC grew its position in Insulet by 21.2% in the fourth quarter. AQR Capital Management LLC now owns 10,840 shares of the medical instruments supplier’s stock worth $1,840,000 after acquiring an additional 1,895 shares in the last quarter. Advisors Asset Management Inc. grew its position in Insulet by 420.6% in the fourth quarter. Advisors Asset Management Inc. now owns 2,176 shares of the medical instruments supplier’s stock worth $373,000 after acquiring an additional 1,758 shares in the last quarter. Ladenburg Thalmann Financial Services Inc. grew its position in Insulet by 129.6% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 3,694 shares of the medical instruments supplier’s stock worth $632,000 after acquiring an additional 2,085 shares in the last quarter. Finally, Geode Capital Management LLC grew its position in Insulet by 10.5% in the fourth quarter. Geode Capital Management LLC now owns 710,167 shares of the medical instruments supplier’s stock worth $121,475,000 after acquiring an additional 67,333 shares in the last quarter.

Several research firms recently commented on PODD. BidaskClub lowered Insulet from a “buy” rating to a “hold” rating in a research report on Friday, July 17th. Morgan Stanley raised their price objective on shares of Insulet from $186.00 to $222.00 and gave the stock an “equal weight” rating in a research note on Friday, May 8th. SVB Leerink raised their price objective on shares of Insulet from $200.00 to $230.00 and gave the stock a “market perform” rating in a research note on Friday, May 8th. Zacks Investment Research downgraded shares of Insulet from a “hold” rating to a “sell” rating and set a $195.00 price objective for the company. in a research note on Thursday, June 11th. Finally, Robert W. Baird raised their price objective on shares of Insulet from $189.00 to $242.00 in a research note on Friday, May 8th. Two investment analysts have rated the stock with a sell rating, eleven have given a hold rating and ten have given a buy rating to the company’s stock. Insulet currently has an average rating of “Hold” and an average target price of $198.10.

In related news, SVP Eric Benjamin sold 14,912 shares of the business’s stock in a transaction that occurred on Thursday, July 23rd. The shares were sold at an average price of $210.00, for a total value of $3,131,520.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 1.10% of the company’s stock.

Insulet stock opened at $203.36 on Friday. The company has a 50 day moving average price of $196.35 and a 200-day moving average price of $190.25. The company has a debt-to-equity ratio of 15.24, a quick ratio of 3.42 and a current ratio of 4.15. Insulet Co. has a fifty-two week low of $115.56 and a fifty-two week high of $228.79. The company has a market capitalization of $12.83 billion, a PE ratio of 2,542.32 and a beta of 0.91.

Insulet (NASDAQ:PODD) last posted its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported ($0.03) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.02) by ($0.01). Insulet had a net margin of 0.66% and a return on equity of 7.66%. The company had revenue of $198.00 million for the quarter, compared to the consensus estimate of $189.61 million. During the same period in the prior year, the firm posted $0.07 EPS. The business’s revenue was up 23.8% on a year-over-year basis. On average, analysts forecast that Insulet Co. will post 0.1 earnings per share for the current year.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company offers Omnipod System, which consists of self-adhesive disposable tubeless Omnipod device (the pod) that delivers insulin into the body; and Personal Diabetes Manager, a handheld wireless device, which programs the Pod.

See Also: What is a Roth IRA?

Institutional Ownership by Quarter for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.